Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

The Journal of pathology - 1 Jan 2013

Anglesio Michael S, Kommoss Stefan, Tolcher Mary C, Clarke Blaise, Galletta Laura, Porter Henry, Damaraju Sambasivarao, Fereday Sian, Winterhoff Boris J, Kalloger Steve E, Senz Janine, Yang Winnie, Steed Helen, Allo Ghassan, Ferguson Sarah, Shaw Patricia, Teoman Attila, Garcia Joaquin J, Schoolmeester John K, Bakkum-Gamez Jamie, Tinker Anna V, Bowtell David D, Huntsman David G, Gilks C Blake, McAlpine Jessica N

Abstract excerpt

Mucinous ovarian carcinomas (MCs) typically do not respond to current conventional therapy. We have previously demonstrated amplification of HER2 in 6 of 33 (18.2%) mucinous ovarian carcinomas (MCs) and presented anecdotal evidence of response with HER2-targeted treatment in a small series of wom...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to Australia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Canada

Share to Gene Amplification

Share to Neoplasm Grading

Share to Neoplasm Recurrence, Local

Share to Proportional Hazards Models

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 22899400
DOI: 10.1002/path.4088

Genes

KRAS
CISH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22899400-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.PMID 22899400Read ↗

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.Semantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

The molecular origin and taxonomy of mucinous ovarian carcinomaSemantic proximity Read ↗

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentSemantic proximity Read ↗

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.Semantic proximity Read ↗

Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.Semantic proximity Read ↗

The mutation and clonality profile of genomically unstable high grade serous ovarian cancer is established early in tumor development and conserved throughout therapy resistanceSemantic proximity Read ↗

Molecular characterization of borderline and malignant Brenner tumors: implications for pathogenesis and therapeutics.Semantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

Therapeutic options for mucinous ovarian carcinoma.Semantic proximity Read ↗

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesSemantic proximity Read ↗

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.